Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Toxicity after post-prostatectomy image-guided intensity-modulated radiotherapy using Australian guidelines.

Chin S, Aherne NJ, Last A, Assareh H, Shakespeare TP.

J Med Imaging Radiat Oncol. 2017 Dec;61(6):804-811. doi: 10.1111/1754-9485.12632. Epub 2017 Jun 17.

PMID:
28623847
2.

Rural radiation therapy ine(quality): Time to bust an urban myth.

Dwyer PM, Aherne NJ, Tahir AR, Hill J, Masoud-Rahbari R, Shakespeare TP.

J Med Imaging Radiat Oncol. 2016 Dec;60(6):781-783. doi: 10.1111/1754-9485.12538. No abstract available.

PMID:
27921391
3.

Long-term decision regret after post-prostatectomy image-guided intensity-modulated radiotherapy.

Shakespeare TP, Chin S, Manuel L, Wen S, Hoffman M, Wilcox SW, Aherne NJ.

J Med Imaging Radiat Oncol. 2017 Feb;61(1):141-145. doi: 10.1111/1754-9485.12508. Epub 2016 Aug 16.

PMID:
27531363
4.

Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation?

Shakespeare TP, Wilcox SW, Aherne NJ.

Onco Targets Ther. 2016 May 11;9:2819-24. doi: 10.2147/OTT.S105174. eCollection 2016.

5.

Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?

Shakespeare TP, Wilcox SW, Aherne NJ.

Onco Targets Ther. 2016 Mar 17;9:1635-9. doi: 10.2147/OTT.S102327. eCollection 2016.

6.

Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: a comparison of Australian series.

Wilcox SW, Aherne NJ, McLachlan CS, McKay MJ, Last AJ, Shakespeare TP.

J Med Imaging Radiat Oncol. 2015 Feb;59(1):125-33. doi: 10.1111/1754-9485.12275. Epub 2015 Jan 15.

PMID:
25588566
7.

Planning magnetic resonance imaging for prostate cancer intensity-modulated radiation therapy: Impact on target volumes, radiotherapy dose and androgen deprivation administration.

Horsley PJ, Aherne NJ, Edwards GV, Benjamin LC, Wilcox SW, McLachlan CS, Assareh H, Welshman R, McKay MJ, Shakespeare TP.

Asia Pac J Clin Oncol. 2015 Mar;11(1):15-21. doi: 10.1111/ajco.12266. Epub 2014 Sep 16.

PMID:
25227727
8.

Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: encouraging results for intermediate- and high-risk prostate cancer.

Wilcox SW, Aherne NJ, Benjamin LC, Wu B, de Campos Silva T, McLachlan CS, McKay MJ, Last AJ, Shakespeare TP.

Onco Targets Ther. 2014 Aug 30;7:1519-23. doi: 10.2147/OTT.S65238. eCollection 2014.

9.

Prevalence of complementary and alternative therapy use by cancer patients undergoing radiation therapy.

Edwards GV, Aherne NJ, Horsley PJ, Benjamin LC, McLachlan CS, McKay MJ, Shakespeare TP.

Asia Pac J Clin Oncol. 2014 Dec;10(4):346-53. doi: 10.1111/ajco.12203. Epub 2014 May 19.

PMID:
24837068
10.

Improved outcomes with intensity modulated radiation therapy combined with temozolomide for newly diagnosed glioblastoma multiforme.

Aherne NJ, Benjamin LC, Horsley PJ, Silva T, Wilcox S, Amalaseelan J, Dwyer P, Tahir AM, Hill J, Last A, Hansen C, McLachlan CS, Lee YL, McKay MJ, Shakespeare TP.

Neurol Res Int. 2014;2014:945620. doi: 10.1155/2014/945620. Epub 2014 Jan 19.

11.

Is "pelvic radiation disease" always the cause of bowel symptoms following prostate cancer intensity-modulated radiotherapy?

Min M, Chua B, Guttner Y, Abraham N, Aherne NJ, Hoffmann M, McKay MJ, Shakespeare TP.

Radiother Oncol. 2014 Feb;110(2):278-83. doi: 10.1016/j.radonc.2013.11.012. Epub 2014 Jan 8.

PMID:
24412017
12.

Prostate Cancer in a Male with Holt-Oram Syndrome: First Clinical Association of the TBX5 Mutation.

Aherne NJ, Rangaswamy G, Thirion P.

Case Rep Urol. 2013;2013:405343. doi: 10.1155/2013/405343. Epub 2013 Aug 5.

13.

Decision regret in men undergoing dose-escalated radiation therapy for prostate cancer.

Steer AN, Aherne NJ, Gorzynska K, Hoffman M, Last A, Hill J, Shakespeare TP.

Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):716-20. doi: 10.1016/j.ijrobp.2013.03.006. Epub 2013 Apr 19.

PMID:
23608238
14.

Rheumatoid nodules mimicking metastatic anal carcinoma in a patient undergoing multimodality treatment.

Aherne NJ, Mincham S, McKay MJ, Hill JD, Last A, Shakespeare TP.

Int J Colorectal Dis. 2013 Oct;28(10):1457-8. doi: 10.1007/s00384-012-1634-0. Epub 2013 Jan 18. No abstract available.

PMID:
23329213
15.
16.

Recurrent malignant pilomatrixoma invading the cranial cavity: Improved local control with adjuvant radiation.

Aherne NJ, Fitzpatrick DA, Gibbons D, Collins CD, Armstrong JG.

J Med Imaging Radiat Oncol. 2009 Feb;53(1):139-41. doi: 10.1111/j.1754-9485.2009.02049.x.

PMID:
19453540
17.

Steroidal antiandrogen administration to treat gonadotropin-releasing hormone analogue-induced orchialgia.

Steer AN, Aherne NJ, Chong VS, Shakespeare TP.

Endocr Pract. 2009 Apr;15(3):246-8.

PMID:
19364694
18.

Post irradiation olfactory neuroblastoma (esthesioneuroblastoma): a case report and up to date review.

McVey GP, Power DG, Aherne NJ, Gibbons D, Carney DN.

Acta Oncol. 2009;48(6):937-40. doi: 10.1080/02841860902759709. No abstract available.

PMID:
19235572
19.

Syndrome of inappropriate antidiuresis (SIAD) in a patient with rectal carcinoma undergoing preoperative radiation.

Aherne NJ, Steer AN, Warrier A, Shakespeare TP.

Int J Colorectal Dis. 2009 Jul;24(7):861-2. doi: 10.1007/s00384-009-0650-1. Epub 2009 Jan 30. No abstract available.

PMID:
19184062
20.

Pilomatrix carcinoma presenting as an extra axial mass: clinicopathological features.

Aherne NJ, Fitzpatrick DA, Gibbons D, Armstrong JG.

Diagn Pathol. 2008 Nov 29;3:47. doi: 10.1186/1746-1596-3-47.

Supplemental Content

Loading ...
Support Center